Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emricasan (Primary)
Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
Focus Therapeutic Use
Acronyms ENCORE-NF
Sponsors Conatus Pharmaceuticals

Most Recent Events

27 Dec 2019 Results published in the Journal of Hepatology
02 May 2019 Primary endpoint has not been met. (Fibrosis improvement by at least one stage without worsening of steatohepatitis), according to a Conatus Pharmaceuticals media release.
21 Mar 2019 Status changed from active, no longer recruiting to completed, according to a Conatus Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com